Variation name (cDNA level) | Variation name (protein level) | Variation status | Variation class |
c.IVS62-160A>G (c.9225-160A>G) | Hemizygous |
wt codon | wt aa | mutant codon | mutant aa | mutational event | mutation type |
AAC | Asn | spl-160 | Spl. | A->G | Ts |
Structure | Key Residue (HCD) | Pyrimidin doublet | CpG |
At the mRNA level | On restriction map |
2ARN:Nl/ins203bp(-160-304 int62 | New restriction site(s): none Lost restriction site(s): none |
Impact on splicing | ||||||||||
Splice site type | Wild type sequence | CV | Mutant type sequence | CV | Variation (%) | |||||
AAGataaac |
| AAGgtaaac |
| 31.7 % |
On isoforms (a blue cell indicates that the corresponding isoform is affected by the mutation) | ||||||
Dp 427c | Dp 427m | Dp 427p | Dp 260 | Dp 140 | Dp 116 | Dp 71 |
Immunofluorescence | ||
dys 1 | dys 2 | dys 3 |
Normal | Normal | Normal |
Western Blot | ||
dys 1 | dys 2 | dys 3 |
Normal size, medium quantity | Normal size, medium quantity |
Sample ID | Patient status | Gender | Transmission | Age of onset | Age of death | Geographic origin |
---594-0-1 | Proband | Male | Familial | FRANCE |
Phenotypic group |
BMD |
+ Mental retardation |
Reference ID | Reference |
1 | Unpublished data |